As malaria continues to pose a significant public health challenge in Nigeria, Geneith Pharmaceuticals Limited has reiterated its commitment to providing reliable and effective treatment options, while calling for responsible use of antimalarial drugs to improve patient outcomes.
In a statement signed by the company’s Chairman, Chief Emmanuel Umenwa, and released to the media, Pharm. Abimbola Bowoto, Assistant General Manager, Sales and Marketing at Geneith Pharmaceuticals, emphasized that although progress has been made in malaria control, persistent issues such as drug resistance and medication misuse remain major setbacks, often aggravated by public misconceptions about side effects.
Bowoto explained that side effects, whether mild or rare, are a normal aspect of medicine use worldwide.
He stressed that adherence to medical advice is essential for reducing risks and maximizing therapeutic benefits, particularly with antimalarial therapies like Camosunate, Geneith’s trusted Artemisinin-based Combination Therapy (ACT) comprising Artesunate and Amodiaquine.
“Camosunate remains one of Nigeria’s most dependable ACTs for uncomplicated malaria, in full alignment with World Health Organization (WHO) recommendations. Its proven efficacy lies in its ability to clear parasites rapidly, relieve symptoms promptly, and offer extended protection due to the long half-life of Amodiaquine,” Bowoto stated.
He cited findings from a 2013 clinical study conducted at the University of Benin Teaching Hospital (UBTH), which confirmed Camosunate’s safety and effectiveness for both adults and children.
The study reported high cure rates, minimal side effects, and strong patient compliance when the product was used as recommended, further cementing its place as a frontline treatment in Nigeria’s malaria response.
The research also showed improved results when Camosunate was taken with meals and sufficient water, guidance that aligns with Geneith’s usage recommendations.
Bowoto noted that most side effects occur when patients fail to follow instructions properly.
“Taking Camosunate after food with sufficient water enhances absorption and minimizes discomfort,” he added.
Designed with patient convenience in mind, Camosunate offers age-specific dosing, including vanilla-flavoured granules for children and a simple three-day regimen for adults, making it a preferred choice among healthcare providers nationwide.
Reaffirming Geneith’s commitment to quality and safety, Bowoto highlighted the company’s focus on integrity, innovation, and regulatory compliance, noting that its secure packaging and advanced traceability systems help protect patients from counterfeit products.
He further called for increased public awareness on proper medicine use, urging healthcare professionals to continue prescribing WHO-approved ACTs and encouraging patients to always complete their treatment courses to prevent relapse and resistance.
“Geneith’s mission goes beyond producing medicines; it is about protecting trust, advancing innovation, and standing firmly with healthcare professionals and communities in the fight against malaria,” Bowoto affirmed.